High Estrogen in Men: Drugs That Cause It and Drugs That Treat It

How Estrogen Works in the Male Body

Men produce estradiol primarily through peripheral aromatization of testosterone in adipose tissue, bone, and brain. The enzyme aromatase (CYP19A1) converts circulating androgens into estrogens, and this process accounts for roughly 80% of male estradiol production [1]. The remaining fraction comes from direct testicular secretion.

Estradiol is not a problem hormone in men. It is necessary. It contributes to bone mineral density maintenance, lipid metabolism, and neurocognitive function [2]. A 2016 analysis published in the New England Journal of Medicine demonstrated that men rendered estrogen-deficient through aromatase inhibition experienced increased fat mass and decreased sexual function within 16 weeks [3]. The clinical target is balance, not elimination.

Problems arise when estradiol climbs above the upper reference limit (generally 40 to 50 pg/mL on liquid chromatography-tandem mass spectrometry assays) or when the testosterone-to-estradiol ratio drops below approximately 10:1. At those levels, men may develop breast tissue proliferation, fluid retention, mood instability, and erectile dysfunction [4]. The Endocrine Society's 2018 guidelines on testosterone therapy acknowledge estradiol monitoring as a reasonable practice in symptomatic patients on TRT, though they stop short of recommending routine aromatase inhibitor co-prescription [5].

Symptoms That Signal Estradiol Is Too High

The clinical picture is recognizable. Gynecomastia (palpable breast tissue extending beyond the areola) is the hallmark finding, affecting an estimated 10 to 25% of men on supraphysiologic testosterone doses [6]. Tenderness often precedes visible enlargement by weeks.

Sexual dysfunction follows a distinct pattern. Men report decreased libido first, then softer erections, then difficulty reaching orgasm. This sequence differs from primary hypogonadism, where libido and erections tend to decline together. Water retention manifests as periorbital puffiness in the morning, tight rings, and a 2 to 5 pound weight gain over days rather than weeks [7].

Mood changes are subtler but consistent across clinical reports. Increased emotional reactivity, tearfulness, and irritability appear more frequently than overt depression. Some men describe a "brain fog" similar to what they experienced before starting testosterone therapy, which can be confusing when their total testosterone level reads normal or high.

A useful clinical framework for triaging these symptoms: if a man on TRT develops two or more of the above complaints AND his sensitive estradiol is above 50 pg/mL, pharmacologic intervention is reasonable. One symptom alone, or elevated estradiol without symptoms, rarely justifies adding another medication.

Drugs That Raise Estrogen in Men

Exogenous Testosterone

Every form of testosterone replacement (injections, gels, pellets, patches) provides substrate for aromatase. Testosterone cypionate 200 mg weekly, a common TRT dose, can raise estradiol into the 50 to 80 pg/mL range in men with higher body fat [8]. Injectable testosterone produces sharper estradiol spikes than transdermal formulations because of the bolus pharmacokinetics. A 2020 retrospective in the Journal of Clinical Endocrinology & Metabolism found that men on intramuscular testosterone had 35% higher peak estradiol levels compared with men using 1% testosterone gel at equivalent steady-state testosterone concentrations [9].

Spironolactone

Spironolactone, prescribed for heart failure, resistant hypertension, and acne, directly stimulates aromatase activity and displaces estradiol from sex hormone-binding globulin (SHBG). Gynecomastia occurs in approximately 9% of men taking 25 to 50 mg daily and rises to 52% at doses above 150 mg daily, according to data from the RALES trial (N=1,663) [10]. The effect is dose-dependent and usually reversible within 3 to 6 months of discontinuation.

Opioids

Chronic opioid therapy suppresses gonadotropin-releasing hormone (GnRH) pulsatility, leading to low testosterone with a relative estrogen excess. A cross-sectional study of uen on long-term opioids found that 74% had testosterone below 300 ng/dL and 29% had estradiol above the upper reference range [11]. Methadone and extended-release morphine carry the highest risk. Buprenorphine appears to have a more favorable hormonal profile.

Antipsychotics and Antiemetics

Dopamine antagonists (risperidone, haloperidol, metoclopramide) raise prolactin, which indirectly upregulates aromatase expression. Risperidone produces gynecomastia in up to 2.3% of adult men, a rate 3 to 5 times higher than quetiapine or aripiprazole [12]. The mechanism is indirect but clinically significant enough that the FDA label for risperidone includes gynecomastia as a reported adverse event.

Other Notable Offenders

Digoxin contains steroid-like structures that bind estrogen receptors directly. Ketoconazole at systemic doses inhibits testosterone synthesis while leaving aromatase activity intact, creating a relative estrogen excess. 5-alpha reductase inhibitors (finasteride, dutasteride) shift the androgen-to-estrogen ratio by blocking conversion of testosterone to dihydrotestosterone, leaving more substrate available for aromatization [13]. The clinical significance of this shift is debated, but some men on finasteride 1 mg daily report breast tenderness.

Aromatase Inhibitors: Anastrozole and Letrozole

Aromatase inhibitors (AIs) block CYP19A1 directly, reducing peripheral estradiol production by 50 to 70% within days of initiation [14]. Two AIs dominate male-focused prescribing.

Anastrozole is the most widely used. Standard dosing in men is 0.5 mg twice weekly or 1 mg twice weekly, far lower than the 1 mg daily breast cancer dose. A 2004 study by Leder et al. published in the Journal of Clinical Endocrinology & Metabolism showed that anastrozole 1 mg daily in healthy older men reduced estradiol by 50% while increasing testosterone by 58%, with bioavailable testosterone rising by 82% [15]. The twice-weekly approach emerged from clinical practice because daily dosing frequently overshoots, driving estradiol below 10 pg/mL, which causes joint pain, mood deterioration, and bone density loss.

Letrozole is more potent (suppresses estradiol by up to 65% at 2.5 mg daily in women) and has a longer half-life of approximately 2 days. In men, dosing is typically 0.25 to 0.5 mg twice weekly. Some clinicians reserve letrozole for men who do not respond adequately to anastrozole, though head-to-head data in males are sparse [16].

The risks of AI therapy in men deserve plain language. Over-suppression of estradiol accelerates bone loss. A prospective study of men on anastrozole for over 12 months showed a 1.8% decline in lumbar spine bone mineral density at 24 months [17]. Lipid profiles may worsen, with LDL cholesterol increasing by 5 to 10% in some reports. Joint stiffness and decreased libido from estradiol levels falling below 15 pg/mL are the most common patient complaints.

Selective Estrogen Receptor Modulators: Tamoxifen and Clomiphene

SERMs do not reduce circulating estradiol. They block estrogen receptors in specific tissues while activating them in others. This tissue-selective mechanism makes them useful when the goal is symptom relief (particularly gynecomastia) without systemic estradiol suppression.

Tamoxifen at 10 to 20 mg daily is the best-studied pharmacologic treatment for male gynecomastia. A 2004 retrospective analysis found that tamoxifen produced partial or complete regression of gynecomastia in 78% of men treated within the first 12 months of symptom onset [18]. Once breast tissue has been present for longer than 12 months, fibrosis replaces glandular proliferation, and the response rate drops below 40%. Tamoxifen also blocks estrogen receptors in breast tissue while maintaining estrogenic activity in bone, which gives it a theoretical safety advantage over aromatase inhibitors for long-term use [19].

Side effects of tamoxifen in men are less frequent than in women because of shorter treatment durations and lower doses. The most reported complaints are decreased libido (paradoxically, given that it raises testosterone via hypothalamic feedback), hot flashes, and leg cramps.

Clomiphene citrate at 25 to 50 mg daily (or every other day) functions as a SERM at the hypothalamus, blocking estrogen negative feedback and increasing LH and FSH secretion. This raises both testosterone and estradiol, but the net effect is usually favorable because testosterone rises proportionally more. A 2012 study in BJU International found that clomiphene 25 mg every other day raised mean testosterone from 309 to 642 ng/dL in hypogonadal men over 3 months, with estradiol increasing modestly from 20 to 28 pg/mL [20]. Clomiphene is not FDA-approved for male hypogonadism and is used off-label, but it remains a first-line option in men who want to preserve fertility while addressing symptoms.

When to Lower Estrogen and When to Leave It Alone

Not every elevated estradiol reading requires treatment. The Endocrine Society's 2018 guideline on testosterone therapy explicitly does not recommend routine AI co-prescription with TRT [5]. The American Urological Association's 2018 guideline on male hypogonadism echoes this position, stating that aromatase inhibitors should be reserved for symptomatic patients with documented elevations [21].

A reasonable clinical algorithm: confirm symptoms, draw a sensitive estradiol level (LC-MS/MS, not direct immunoassay, which overestimates at low levels and underestimates at high levels), and then intervene only if both criteria are met. If the estradiol is 45 to 60 pg/mL with mild symptoms, non-pharmacologic strategies should come first. Reducing injection frequency (switching from weekly to twice-weekly dosing splits the estradiol peak), lowering the testosterone dose by 10 to 20%, and losing 5 to 10% of body weight can each reduce estradiol by 15 to 30% [22].

For men with estradiol above 60 pg/mL and clear symptoms (progressive gynecomastia, significant erectile dysfunction, disabling edema), pharmacologic intervention with anastrozole 0.5 mg twice weekly is a reasonable starting point. Recheck labs at 4 to 6 weeks. The target is symptomatic relief with estradiol in the 20 to 35 pg/mL range, not the lowest possible number.

The Role of Body Composition

Adipose tissue is the primary site of peripheral aromatization in men. A 2012 analysis in Obesity Reviews demonstrated a linear relationship between body mass index and serum estradiol, with each 5-unit BMI increase corresponding to an approximate 10 pg/mL rise in estradiol [23]. This means that a man with a BMI of 35 may have baseline estradiol levels 20 pg/mL higher than an otherwise identical man with a BMI of 25, before any medications enter the picture.

Weight loss directly reduces aromatase expression. Bariatric surgery patients show a mean 40% decline in estradiol within 6 months of surgery, closely tracking the reduction in visceral fat volume [24]. For men on TRT with mildly elevated estradiol, a 10% weight loss may eliminate the need for an aromatase inhibitor entirely.

This relationship also explains why some men on identical TRT protocols develop estrogenic symptoms while others do not. Body fat percentage, not just testosterone dose, determines aromatization rate. Clinicians who prescribe TRT without addressing body composition are treating half the equation.

Monitoring Protocol on Estrogen-Modifying Therapy

Once a man starts an aromatase inhibitor or SERM, structured monitoring prevents both under-treatment and the more dangerous over-suppression.

Draw baseline labs before initiating therapy: sensitive estradiol (LC-MS/MS), total testosterone, free testosterone (equilibrium dialysis or calculated), complete metabolic panel, and lipid panel. Add a DEXA scan if the patient will be on an aromatase inhibitor for longer than 6 months [17].

Recheck sensitive estradiol and testosterone at 4 to 6 weeks. If estradiol has dropped below 15 pg/mL, reduce the AI dose or frequency immediately. Joint pain, new mood symptoms, or decreased libido at follow-up should prompt a lab draw even if the scheduled check is weeks away.

At 6 months, repeat lipid panel and reassess symptom status. At 12 months on an AI, repeat DEXA. If bone mineral density has declined by more than 3%, consider switching to tamoxifen or discontinuing the AI if symptoms have resolved [25].

The goal of monitoring is to keep estradiol in a physiologically appropriate range (20 to 35 pg/mL for most men) while confirming that the intervention is actually resolving the symptoms that prompted it. An estradiol of 28 pg/mL means nothing if the patient still has progressive gynecomastia. Conversely, mild lab elevation without symptoms does not justify indefinite pharmacotherapy.